EMLA Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Emla, and what generic alternatives are available?

Emla is a drug marketed by Teva Branded Pharm and Astrazeneca and is included in two NDAs.

The generic ingredient in EMLA is lidocaine; prilocaine. There are twenty-nine drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the lidocaine; prilocaine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Emla

A generic version of EMLA was approved as lidocaine; prilocaine by FOUGERA PHARMS on August 18^th, 2003.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for EMLA?
What are the global sales for EMLA?
What is Average Wholesale Price for EMLA?

Summary for EMLA

US Patents:	0
Applicants:	2
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	5
Patent Applications:	100
DailyMed Link:	EMLA at DailyMed

Drug patent expirations by year for EMLA

US Patents and Regulatory Information for EMLA

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Branded Pharm	EMLA	lidocaine; prilocaine	CREAM;TOPICAL	019941-001	Dec 30, 1992		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Astrazeneca	EMLA	lidocaine; prilocaine	DISC;TOPICAL	020962-001	Feb 4, 1998		DISCN	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for EMLA

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Teva Branded Pharm	EMLA	lidocaine; prilocaine	CREAM;TOPICAL	019941-001	Dec 30, 1992	⤷ Sign Up	⤷ Sign Up
Teva Branded Pharm	EMLA	lidocaine; prilocaine	CREAM;TOPICAL	019941-001	Dec 30, 1992	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

EU/EMA Drug Approvals for EMLA

Subscribe to access the full database, or Sign Up
Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Recordati Ireland Ltd.	Fortacin	lidocaine, prilocaine	EMEA/H/C/002693 Treatment of primary premature ejaculation in adult men.	Authorised	no	no	no	2013-11-15
Plethora Pharma Solutions Limited	Senstend	lidocaine, prilocaine	EMEA/H/C/005298 Senstend is indicated for the treatment of primary premature ejaculation in adult men.	Withdrawn	no	no	no	2019-11-14
>Company	>Drugname	>Inn	>Product Number / Indication	>Status	>Generic	>Biosimilar	>Orphan	>Marketing Authorisation	>Marketing Refusal

International Patents for EMLA

See the table below for patents covering EMLA around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Germany	2851369		⤷ Sign Up
Sweden	432192	EN LOKALANESTETISK EMULSIONSALVA FOR UTVERTES BRUK AV TYPEN OLJA-I-VATTEN-EMULSION	⤷ Sign Up
New Zealand	189026	TOPICAL LOCAL ANAESTHETIC COMPOSITIONS	⤷ Sign Up
Canada	1118350	MELANGE ANESTHESIQUE LOCAL POUR APPLICATION TOPIQUE, PROCEDE DE PREPARATION ET METHODE POUR OBTENIR UNE ANESTHESIE LOCALE (LOCAL ANESTHETIC MIXTURE FOR TOPICAL APPLICATION, PROCESS FOR ITS PREPARATION, AS WELL AS METHOD FOR OBTAINING LOCAL ANESTHESIA)	⤷ Sign Up
Sweden	7713617		⤷ Sign Up
Australia	524406		⤷ Sign Up
Canada	1113399	ANESTHESIQUE LOCAL ET ANTISUDORIFIQUE (LOCAL ANAESTHETIC AS ANTIPERSPIRANT)	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

AI Research Assistant

Questions you can ask:

Summary for EMLA

Make Better Decisions: Try a trial or see plans & pricing